Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
Desai D, Khan AR, Soneja M, Mittal A, Naik S, Kodan P, Mandal A, Maher GT, Kumar R, Agarwal A, Gowda NR, H V, Kumar P, Pandey S, Pandey RM, Kumar A, Ray A, Jorwal P, Nischal N, Choudhary A, Brijwal M, Madan K, Lodha R, Sinha S, Dar L, Wig N, Guleria R.
Desai D, et al. Among authors: h v.
Lancet Infect Dis. 2022 Mar;22(3):349-356. doi: 10.1016/S1473-3099(21)00674-5. Epub 2021 Nov 23.
Lancet Infect Dis. 2022.
PMID: 34826383
Free PMC article.
Clinical Trial.
INTERPRETATION: This study shows the effectiveness of two doses of BBV152 against symptomatic COVID-19 in the context of a huge surge in cases, presumably dominated by the potentially immune-evasive delta (B.1.617.2) variant of SARS-CoV-2. Our findings support the ongoing …
INTERPRETATION: This study shows the effectiveness of two doses of BBV152 against symptomatic COVID-19 in the context of a huge surge in cas …